Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
grade D 0.74 -3.90% -0.03
SCYX closed down 3.9 percent on Friday, January 18, 2019, on 74 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical SCYX trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 NR7 Range Contraction -3.90%
Jan 17 Wide Bands Range Expansion -3.90%
Jan 17 Overbought Stochastic Strength -3.90%
Jan 16 Wide Bands Range Expansion -7.50%
Jan 16 Overbought Stochastic Strength -7.50%
Jan 16 Up 3 Days in a Row Strength -7.50%
Jan 16 Up 4 Days in a Row Strength -7.50%
Jan 15 Calm After Storm Range Contraction -6.33%

Older signals for SCYX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Is SCYX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.15
52 Week Low 0.35
Average Volume 409,373
200-Day Moving Average 1.2341
50-Day Moving Average 0.6796
20-Day Moving Average 0.6147
10-Day Moving Average 0.7495
Average True Range 0.0808
ADX 34.71
+DI 24.7987
-DI 15.55
Chandelier Exit (Long, 3 ATRs ) 0.5976
Chandelier Exit (Short, 3 ATRs ) 0.5924
Upper Bollinger Band 0.9075
Lower Bollinger Band 0.3219
Percent B (%b) 0.71
BandWidth 95.265983
MACD Line 0.0402
MACD Signal Line 0.0137
MACD Histogram 0.0265
Fundamentals Value
Market Cap 19.77 Million
Num Shares 26.7 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -0.77
Price-to-Sales 193.40
Price-to-Book 1.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.85
Resistance 3 (R3) 0.85 0.83 0.83
Resistance 2 (R2) 0.83 0.80 0.82 0.82
Resistance 1 (R1) 0.78 0.78 0.77 0.78 0.82
Pivot Point 0.76 0.76 0.75 0.75 0.76
Support 1 (S1) 0.71 0.73 0.70 0.71 0.66
Support 2 (S2) 0.69 0.71 0.68 0.66
Support 3 (S3) 0.64 0.69 0.65
Support 4 (S4) 0.64